ArticleThe Journal of experimental medicine2000

A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.

T Yokomizo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.